Shanghai RAAS Blood Products Co., Ltd. Environmental Analytics
Environmental and financial analysis dashboard for Shanghai RAAS Blood Products Co., Ltd.. Industry: MANUFACTURING
Company Overview for Shanghai RAAS Blood Products Co., Ltd.
Highlights
Showing data for FY2022
Operational Environmental Cost
$10m
Operational Environmental Cost Intensity
1.11%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$8.69m
Decoupling Rate (2020-2022)
-62%
Adjusted EBITDA
$343m
Adjusted EBITDA Margin
36%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| 113.10% | 39.24% | 20.82% | ||
| 0.13% | 0.18% | 0.17% | 0.18% | |
| 180.41% | 157.54% | 26.42% | ||
| 0.29% | 0.51% | 0.93% | 0.99% | |
| $2m | $5m | $10m | $13m | |
| 159.36% | 127.14% | 25.54% | ||
| 0.42% | 0.69% | 1.11% | 1.17% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
36%
Adjusted EBIT Margin
34%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$422m | $673m | $945m | $1,123m | |
| 59.31% | 40.42% | 18.87% | ||
$173m | $406m | $591m | $789m | |
| 40.96% | 60.39% | 62.57% | 70.28% | |
$249m | $267m | $354m | $334m | |
| 59.04% | 39.61% | 37.43% | 29.72% | |
$226m | $242m | $327m | $311m | |
| 53.50% | 35.90% | 34.62% | 27.68% | |
| ENVIRONMENTAL COST DATA | ||||
$2m | $5m | $10m | $13m | |
| 0.42% | 0.69% | 1.11% | 1.17% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$248m | $262m | $343m | $321m | |
| 58.61% | 38.93% | 36.32% | 28.55% | |
$224m | $237m | $317m | $298m | |
| 53.08% | 35.22% | 33.51% | 26.51% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.17%
Scope 2 (% of Sales)
0.93%
Operational Environmental Cost Intensity
1.11%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
Shanghai RAAS Blood Products Co., Ltd. | CN | $10m | 1.11% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022